In its most recent safety review of Pradaxa (dabigatrin), the U.S. Food and Drug Administration (FDA) says that the risk of serious bleeding associated with the new anticlotting drug appears to be no higher than the bleeding rates associated with warfarin (Coumadin), the decades-old anticoagulant drug Pradaxa was largely designed to replace. Although FDA regulators haven’t changed their recommendations for Pradaxa, they advised health care professionals prescribing the drug to carefully follow dosing recommendations on the drug’s label, especially when using it to treat patients with renal (kidney) impairment. However, the FDA fails to mention what is perhaps the drug’s ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.